An asset exchange agreement with Medarex to gain all rights to HuMax-Inflam(TM), now known as HuMax-IL8(TM). Genmab plans to develop the antibody for the treatment of glioblastoma, a cancer of the central nervous system.
Amending a pivotal study of HuMax-CD20(R) (ofatumumab) to treat non-hodgkin's lymphoma from two arms to a single arm study.
Genmab is maintaining its financial guidance for the year. We expect our revenues to benefit from the achievement of certain development milestones in the fourth quarter of 2007 and we continue to project a 2007 operating loss of DKK 385 to 435 million and a net loss in the range of DKK 260 to 310 million.
Genmab's projected December 31, 2007 cash position is expected to be in the range of DKK 3.8 to 3.9 billion.
Genmab will hold a conference call to discuss the results for the nine month period ended September 30, 2007 tomorrow, Wednesday, October 31, 2007, at
2.00 pm CET 1.00 pm GMT 9.00 am EDT
The conference call will be held in English.
The dial in numbers are as follows:
+1-800-231-9012 (in the US) and ask for the Genmab conference call +1-719-457-2706 (outside the US) and ask for the Genmab conference call
A live webcast of the call and relevant slides will be available at http://www.genmab.com. The webcast will also be archived on Genmab's website.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances t
|SOURCE Genmab A/S|
Copyright©2007 PR Newswire.
All rights reserved